Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1272455

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Chan, Arlene; Delaloge, Suzette; Holmes, Frankie A; Moy, Beverly; Iwata, Hiroji; Harvey, Vernon J; Robert, Nicholas J; Silovski, Tajana; Gokmen, Erhan; von Minckwitz, Gunter et al.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial // The Lancet Oncology, 17 (2016), 3; 367-377 doi:10.1016/s1470-2045(15)00551-3 (međunarodna recenzija, članak, stručni)

CROSBI ID: 1272455 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
(Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial)

Autori
Chan, Arlene ; Delaloge, Suzette ; Holmes, Frankie A ; Moy, Beverly ; Iwata, Hiroji ; Harvey, Vernon J ; Robert, Nicholas J ; Silovski, Tajana ; Gokmen, Erhan ; von Minckwitz, Gunter ; Ejlertsen, Bent ; Chia, Stephen K L ; Mansi, Janine ; Barrios, Carlos H ; Gnant, Michael ; Buyse, Marc ; Gore, Ira ; Smith, John ; Harker, Graydon ; Masuda, Norikazu ; Petrakova, Katarina ; Zotano, Angel Guerrero ; Iannotti, Nicholas ; Rodriguez, Gladys ; Tassone, Pierfrancesco ; Wong, Alvin ; Bryce, Richard ; Ye, Yining ; Yao, Bin ; Martin, Miguel

Izvornik
The Lancet Oncology (1470-2045) 17 (2016), 3; 367-377

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
HER2-positive breast cancer, adjuvant therapy, Neratinib, survival

Sažetak
Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab- based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Klinički bolnički centar Zagreb

Profili:

Avatar Url Tajana Silovski (autor)

Poveznice na cjeloviti tekst rada:

doi pubmed.ncbi.nlm.nih.gov www.thelancet.com

Citiraj ovu publikaciju:

Chan, Arlene; Delaloge, Suzette; Holmes, Frankie A; Moy, Beverly; Iwata, Hiroji; Harvey, Vernon J; Robert, Nicholas J; Silovski, Tajana; Gokmen, Erhan; von Minckwitz, Gunter et al.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial // The Lancet Oncology, 17 (2016), 3; 367-377 doi:10.1016/s1470-2045(15)00551-3 (međunarodna recenzija, članak, stručni)
Chan, A., Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, V., Robert, N., Silovski, T., Gokmen, E. & von Minckwitz, G. (2016) Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 17 (3), 367-377 doi:10.1016/s1470-2045(15)00551-3.
@article{article, author = {Chan, Arlene and Delaloge, Suzette and Holmes, Frankie A and Moy, Beverly and Iwata, Hiroji and Harvey, Vernon J and Robert, Nicholas J and Silovski, Tajana and Gokmen, Erhan and von Minckwitz, Gunter and Ejlertsen, Bent and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Buyse, Marc and Gore, Ira and Smith, John and Harker, Graydon and Masuda, Norikazu and Petrakova, Katarina and Zotano, Angel Guerrero and Iannotti, Nicholas and Rodriguez, Gladys and Tassone, Pierfrancesco and Wong, Alvin and Bryce, Richard and Ye, Yining and Yao, Bin and Martin, Miguel}, year = {2016}, pages = {367-377}, DOI = {10.1016/s1470-2045(15)00551-3}, keywords = {HER2-positive breast cancer, adjuvant therapy, Neratinib, survival}, journal = {The Lancet Oncology}, doi = {10.1016/s1470-2045(15)00551-3}, volume = {17}, number = {3}, issn = {1470-2045}, title = {Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial}, keyword = {HER2-positive breast cancer, adjuvant therapy, Neratinib, survival} }
@article{article, author = {Chan, Arlene and Delaloge, Suzette and Holmes, Frankie A and Moy, Beverly and Iwata, Hiroji and Harvey, Vernon J and Robert, Nicholas J and Silovski, Tajana and Gokmen, Erhan and von Minckwitz, Gunter and Ejlertsen, Bent and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Buyse, Marc and Gore, Ira and Smith, John and Harker, Graydon and Masuda, Norikazu and Petrakova, Katarina and Zotano, Angel Guerrero and Iannotti, Nicholas and Rodriguez, Gladys and Tassone, Pierfrancesco and Wong, Alvin and Bryce, Richard and Ye, Yining and Yao, Bin and Martin, Miguel}, year = {2016}, pages = {367-377}, DOI = {10.1016/s1470-2045(15)00551-3}, keywords = {HER2-positive breast cancer, adjuvant therapy, Neratinib, survival}, journal = {The Lancet Oncology}, doi = {10.1016/s1470-2045(15)00551-3}, volume = {17}, number = {3}, issn = {1470-2045}, title = {Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial}, keyword = {HER2-positive breast cancer, adjuvant therapy, Neratinib, survival} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.